Women’s health companies secured a record $1.55bn in funding in 2025, hinting that investors’ faith is growing in this sector.
According to a global women’s health investment report from W Group, disclosed equity secured by companies in the space last year was up 41% compared to 2024. The report tracked more than 500 funding stories and around 164 disclosed rounds of equity across clinical and consumer categories.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In total, 85 companies raised equity in 2025, the highest single-year count ever recorded according to W Group, and 10 rounds reached $50m or more, double that seen in 2024.
In 2025, women’s health investments favoured clinically focused companies rather than lifestyle or consumer-only products. Highlights include Visana Health’s $24m Series A to scale its virtual-first women’s clinic, and SheMed’s $50m – also Series A – to advance its female-focused digital healthcare and medical weight loss platform. Meanwhile, ReproNovo netted a $65m Series A for its pipeline that includes therapies for women’s fertility.
Women’s health has long struggled with consistent investment, with many companies hitting a growth cliff when trying to scale beyond early financing rounds. The W Group report alluded to this, highlighting a Series A bottleneck. According to its analysis, up to 40 companies raise pre-seed and seed rounds each year, though only around 20 to 25 of these reach Series A, and many companies that raised seed rounds in 2024 did not raise again in 2025.
This is only one setback against overall improvement, however. Money has stopped concentrating at the top, which the report highlights as the “headline” finding. In 2024, the three largest rounds accounted for 39% of all disclosed capital; in 2025, that share fell to 32%, as funding to companies outside the top three grew 56% year on year.
“2025 was the biggest year women’s health has ever had, and the most important finding isn’t the headline number. It’s that the money has stopped pooling at the top. Capital is reaching more companies, more categories and more countries than ever before,” said Molly Taylor, head of content at W Group.
Taylor adds that closing the Series A gap is the most important move for the sector’s continued growth in 2026.
There are other gaps that can be closed. A research collaboration between McKinsey & Company and the World Economic Forum found that addressing the more time women spend in poor health relative to men would not only improve the health and lives of millions of women but also could boost the global economy by at least $1tn annually by 2040.
Success stories in women’s health are becoming more frequent. Midi Health secured $50m in a Series C round in October 2025, expanding its virtual menopause and midlife women’s healthcare platform. Gameto also closed a $44m Series C round to advance its stem cell-based fertility treatment into Phase III clinical trials. More capital is flowing into the sector, too, from philanthropic organisations. The Bill & Melinda Gates Foundation has pledged a $2.5bn commitment through 2030 for women’s health R&D, marking one of the largest outlays ever for the sector.
